Interaction Guide · Research summary

Can I take Radix Et Rhizoma Valerianae with Lorazepam?

Review Radix Et Rhizoma Valerianae with Lorazepam: possible adverse effects, preparation details, evidence limits, and sources.

Prepared by Dr. Edward M.Kim, PharmD · Clinical Director, SupplementSafety editorial team

Research summary published · Prepared · Editorial update

The short answer

Identify the valerian species before using this root product with lorazepam. Its inventory name alone does not establish which evidence applies.

What this answer covers

Radix et Rhizoma Valerianae has unresolved species identity; Valeriana officinalis evidence applies only after a match is confirmed.

Supplement or preparation
Radix et Rhizoma Valerianae
Medication ingredient
lorazepam

Start with the botanical identity

Ask the pharmacist to confirm the Latin species, root or rhizome, extraction method and other ingredients. Do not assume the inventory name means Valeriana officinalis.

What the guidance supports

NCCIH advises against Valeriana officinalis with sedatives because sleep-inducing effects are possible. This precaution depends on identifying the actual product.

The reported combination used two identified herbs

A lorazepam case involved both Valeriana officinalis and passionflower, with dizziness, shaking and fatigue. It cannot identify the species in your root product or isolate valerian as the cause.

Watch for impaired alertness

Lorazepam can affect alertness and coordination. Avoid driving if affected. Seek urgent help for severe difficulty waking or breathing, and tell the prescriber about alcohol, opioids and all other sedating products.

Evidence and practical considerations

Side effects & toxicity

Identity-specific review and conditional alertness precaution are appropriate; exact-pair risk magnitude remains unmeasured.

Exact scope
Radix et Rhizoma Valerianae has unresolved species identity; Valeriana officinalis evidence applies only after a match is confirmed. with Exact oral lorazepam tablets. Rapid conjugation to lorazepam glucuronide, which has no demonstrable CNS activity in animals. Oral tablet scope; injected lorazepam is not assigned the same supplement evidence.
Medication form and route
oral
Timing or duration
Source-specific single-dose, repeated-dose and observational exposures distinguished.

What remains uncertain

  • Unknown root species cannot be assigned V. officinalis evidence. The lorazepam case also included passionflower, leaving causality and extract-specific risk uncertain.

Factors that may matter: preparation and plant part; clinical indication; dose; other medicines; baseline alertness.

Research conclusion: insufficient evidence · Evidence assessment: low

Read the supporting source summaries

Source 1: current product label

dailymed.nlm.nih.gov · Source check Sep 10, 2026

Population: Patients prescribed oral lorazepam.

Can impair alertness and coordination; other CNS depressants can increase impairment. Opioid combinations have a specific respiratory-depression warning. Dependence and withdrawal require supervised changes. Rapid conjugation to lorazepam glucuronide, which has no demonstrable CNS activity in animals. Oral tablet scope; injected lorazepam is not assigned the same supplement evidence.

How this applies: Exact IN and labeled oral formulation; route, salt and metabolite distinctions retained.

No quantified risk for every herb or universal protective spacing interval. Opioid-specific evidence does not prove equal botanical respiratory risk.

Source 2: official guidance

nccih.nih.gov · Source check Sep 10, 2026

Population: People considering the specified supplement.

Possible but unproven sleep-inducing effect; advises against use with alcohol or sedatives. Mental dullness can occur; long-term safety is uncertain.

How this applies: Preparation-specific context; not a directly measured lorazepam interaction.

No lorazepam interaction trial. Chronic use can be followed by withdrawal symptoms when stopped abruptly.

Source 3: original human study

pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026

Population: Twelve healthy volunteers.

Alprazolam peak concentration increased modestly, but AUC and elimination half-life did not change significantly.

How this applies: Original named medication and preparation only; indirect evidence for lorazepam. Comparator arms are not coadministration.

PK study is not a clinical sedation safety trial. Exact extract/species cannot resolve an unidentified valerian-root inventory item.

Source 4: original case report

pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026

Population: One patient with generalized anxiety disorder.

Hand shaking, dizziness, throbbing and muscular fatigue were reported; authors suspected additive or synergistic activity.

How this applies: Exact lorazepam but identified V. officinalis plus passionflower does not resolve unknown inventory root species.

Both herbs were used together; cannot isolate passionflower, prove receptor mechanism or quantify risk. Abstract only; no coma or respiratory arrest established.

Research assessment: · Open full citations ↗

Review and change history

Publication status
Published research summary
Clinical review
Not yet recorded
DateUpdate
Article prepared
Current exact available claims adjudicated using original captures and explicit identity and comparator limits.
Research summary published

Article revision: 5754f8eafde5baaa

This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.

Full citations require verification. Reading this answer and the source summaries does not.

Taking other supplements or medications?

Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.

Open the interaction checker

Information, not medical advice. Do not change prescribed treatment based on this guide.